Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Brian G.M. Durie, MD, Shaji K. Kumar, MD, Saad Z. Usmani, MD, Bareng A.S. Nonyane, Eric A. Ammann, Annette Lam, Rachel Kobos, MD, Eric M Maiese, PhD, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 1830.

https://doi.org/10.1182/blood-2019-122937

Published: 2019

Journal Articles

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Katja C. Weisel, MD, Sujith Dhanasiri, Aline Gauthier, Amie Padhiar, Eva Casal, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 2201.

https://doi.org/10.1182/blood-2019-123639

Published: 2019

Journal Articles

Laminin G Domains of Protein S Bind and Inhibit Fixa

Sabyasachi Chatterjee, PhD MSc, BSc, Amber Sylvain, Undergraduate Student, Satish Pilli, PhD, Whitney Fant, MS, Doerte R. Fricke, MS, Terry Watt, PhD, Rinku Majumder, PhD

Blood (2019) 134 (Supplement_1): 3624.

https://doi.org/10.1182/blood-2019-127112

Published: 2019

Journal Articles

Fibrin As a Target for Glioblastoma Detection and Treatment

Lynn M Knowles, PhD, Carolin Wolter, MS, Ralf Ketter, MD, Steffi Urbschat, PhD, Stefan Linsler, MD, Simon Müller, MD, Andreas Müller, PhD, Hermann Eichler, Jan Pilch, MD

Blood (2019) 134 (Supplement_1): 3630.

https://doi.org/10.1182/blood-2019-124089

Published: 2019

Journal Articles

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

Simone Critchlow, Miranda Cooper, Ilse van Oostrum, Verna L Welch, PhD MPH, T. Alexander Russell-Smith

Blood (2019) 134 (Supplement_1): 3427.

https://doi.org/10.1182/blood-2019-123454

Published: 2019

Journal Articles

CNS Prophylaxis in Diffuse Large B-Cell Lymphoma & Its Outcomes- an Institutional Review

Raju Vaddepally, MDMBBS, Angie Adhami, MD, Charles Siedlecki, Philip Kuriakose, MD

Blood (2019) 134 (Supplement_1): 5348.

https://doi.org/10.1182/blood-2019-131483

Published: 2019

Journal Articles

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Sophie Van Beekhuizen, MSc, Timothy J Bell, MHA, Ana Gezin, MSc, Joseph C Cappelleri, PhD MPH, MS, Bart Heeg, PhD, Carl Selya-Hammer, MSc, Majed Charaan, MSc, MBA, Geoffrey Chan, MD

Blood (2019) 134 (Supplement_1): 5846.

https://doi.org/10.1182/blood-2019-125852

Published: 2019

Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD

Blood (2018) 132 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2018-99-111931

Published: 2018

Journal Articles

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Geoffrey Chan, MD, Gabriel Tremblay, DBA, MSc, BS

Blood (2018) 132 (Supplement 1): 1429.

https://doi.org/10.1182/blood-2018-99-111971

Published: 2018

Journal Articles

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Greta Lozano-Ortega, MSc, Basia Rogula, Karissa Johnston, Julie Villeneuve, Andriy Moshyk, Heather O'Brien, Clara Chen, PhD BS, MS, Joseph M. Connors, MD

Blood (2018) 132 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2018-99-111278

Published: 2018

Journal Articles

Novel Therapeutic Targeting of UHRF1 Restores 5'-Azacytidine Response in Resistant Acute Myeloid Leukemia

Anup Kumar Singh, MS, PhD, Xiaochun Yu, MD PhD

Blood (2018) 132 (Supplement 1): 1356.

https://doi.org/10.1182/blood-2018-99-115735

Published: 2018

Journal Articles

Determination of the Structural Changes Accompanying Binding of Protein S to Factor IX a

Sabyasachi Chatterjee, PhD MSc, BSc, Jessie J. Guidry, BS, William E Plautz, BS, Terry Watt, PhD, Rinku Majumder, PhD

Blood (2018) 132 (Supplement 1): 20.

https://doi.org/10.1182/blood-2018-99-118843

Published: 2018

Journal Articles

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matthias Stelljes, MD, Yun Su, MD MPH, MS, Kyle Fahrbach, PhD, Erik Vandendries, MD PhD, Veronique Page, M.Sc, Uchenna Onyekwere, MD MPh, Yunyang Wang, M.Sc, M.Pharm, Joseph C. Cappelleri, PhD MPH, MS, Irina Proskorovsky, M.Sc

Blood (2017) 130 (Supplement 1): 2558.

https://doi.org/10.1182/blood.V130.Suppl_1.2558.2558

Published: 2017

Journal Articles

Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Gabriel Tremblay, DBA, MSc, BS, Bhakti Arondekar, BPharm, MBA, PhD, Geoffrey Chan, MD, Anastasiya Shor, PharmD, Anna Forsythe, PharmD, MSc, MBA, Su Yun, MD MPH

Blood (2017) 130 (Supplement 1): 5665.

https://doi.org/10.1182/blood.V130.Suppl_1.5665.5665

Published: 2017

Journal Articles

Patient-Derived Xenograft Model in B-Cell Lymphoma: A Platform for a Personalized Clinical Trial

Taylor Bell, Hui Zhang, Makhdum Ahmed, MD MPH, Hui Guo, MD PhD, Carrie J Li, Yang Liu, PhD, Laura T Lam, PhD, Zhihong Chen, Jack Wang, Victoria Zhang, Krystle Nomie, PhD, Liang Zhang, MD PhD, Michael Wang, MD

Blood (2016) 128 (22): 1839.

https://doi.org/10.1182/blood.V128.22.1839.1839

Published: 2016

Journal Articles

Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice

Rituparna Das, PhD, Till Strowig, PhD, Rakesh Verma, PhD, Srinivas Koduru, PhD, Anja Hafemann, PhD, Stephanie Hopf, Mehmet H. Kocoglu, MD, Chiara Borsotti, PhD, Lin Zhang, Andrew R Branagan, MD, Elizabeth Eynon, PhD, Markus Manz, MD, Richard Flavell, PhD, Madhav V Dhodapkar, MD

Blood (2015) 126 (23): 120.

https://doi.org/10.1182/blood.V126.23.120.120

Published: 2015

Journal Articles

Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells

Rakesh Verma, PhD, Till Strowig, PhD, Rituparna Das, PhD, Srinivas Koduru, PhD, Anja Hafemann, PhD, Stephanie Hopf, Mehmet H. Kocoglu, MD, Chiara Borsotti, PhD, Lin Zhang, Andrew R Branagan, MD, Elizabeth Eynon, PhD, Markus Manz, MD, Richard Flavell, PhD, Madhav V Dhodapkar, MD

Blood (2015) 126 (23): 22.

https://doi.org/10.1182/blood.V126.23.22.22

Published: 2015

Journal Articles

Long-Range Allosteric Linkage Between Exosites Reciprocally Regulates the Zymogenicity of Prothrombin Derivatives

Joseph A. Micucci, PhD, Parvathi Kamath, PhD, Anuja Khan, PhD, Paul E. Bock, PhD, Sriram Krishnaswamy, PhD

Blood (2015) 126 (23): 122.

https://doi.org/10.1182/blood.V126.23.122.122

Published: 2015

Journal Articles

Multiple Brain Hemorrhages on Presentation in a Patient with Accelerated Phase Chronic Myeloid Leukemia and Subsequent CNS Blast Crisis Despite Systemic Complete Molecular Response: Possible Role of CNS Bleed in Leukemia Proliferation

Aleem Aamer, MBBS, FRCP, FRCPath, Fatmah Al Wusibai, MBBS, Khalid AlSaleh, MBBS, FRCPC, MRCP, Fatma Alqahtani, MBBS, KSU fellowship, Zafar Iqbal, PhD, Naeem A. Chaudhri, MD FACP, Abdul Kareem M Al-Momen, MD FRCPC

Blood (2015) 126 (23): 5153.

https://doi.org/10.1182/blood.V126.23.5153.5153

Published: 2015

Journal Articles

A Novel ICAM-1/CD54 Antibody Identified By Phage Display with Potent Pre-Clinical Anti-Myeloma Activity

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 2095.

https://doi.org/10.1182/blood.V124.21.2095.2095

Published: 2014

NARROW

Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM)

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Laminin G Domains of Protein S Bind and Inhibit Fixa

Fibrin As a Target for Glioblastoma Detection and Treatment

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

CNS Prophylaxis in Diffuse Large B-Cell Lymphoma & Its Outcomes- an Institutional Review

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Novel Therapeutic Targeting of UHRF1 Restores 5'-Azacytidine Response in Resistant Acute Myeloid Leukemia

Determination of the Structural Changes Accompanying Binding of Protein S to Factor IX a

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Patient-Derived Xenograft Model in B-Cell Lymphoma: A Platform for a Personalized Clinical Trial

Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice

Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells

Long-Range Allosteric Linkage Between Exosites Reciprocally Regulates the Zymogenicity of Prothrombin Derivatives

Multiple Brain Hemorrhages on Presentation in a Patient with Accelerated Phase Chronic Myeloid Leukemia and Subsequent CNS Blast Crisis Despite Systemic Complete Molecular Response: Possible Role of CNS Bleed in Leukemia Proliferation

A Novel ICAM-1/CD54 Antibody Identified By Phage Display with Potent Pre-Clinical Anti-Myeloma Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only